CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. (July 2021)

• Record Type: Journal Article
• Authors: Chintala, Navin K.; Restle, David; Quach, Hue; Saini, Jasmeen; Bellis, Rebecca; Offin, Michael; Beattie, Jason; Adusumilli, Prasad S.
• Is Part Of: Lung cancer. Volume 157(2021)
• Page Start: 48
• Page End: 59
• Publication Date: 2021-07
• Subjects: APC antigen-presenting cell -- BiTE bispecific T-cell engager -- CAR chimeric antigen receptor -- CSPG4 chondroitin sulfate proteoglycan 4 -- DNR dominant negative receptor -- FAP fibroblast activation protein -- MHC major histocompatibility complex -- MPM malignant pleural mesothelioma -- MSLN mesothelin -- PD-1 programmed cell death protein 1 -- PD-L1 programed death ligand 1 -- TAA tumor-associated antigen -- TCR T-cell receptor -- TIL tumor-infiltrating lymphocyte -- scFv single-chain variable fragment -- STING stimulator of interferon genes; Adoptive cell therapy -- Malignant pleural mesothelioma -- Pleural cancers -- Locoregional delivery; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2021.05.004
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Tumor antigen-targeted CAR T-cell therapy is effective for leukemia and lymphoma. CAR T-cell therapy is in phase I/II clinical trials for pleural mesothelioma. Regional delivery of CAR T cells achieve systemic immunity. Combination of CAR T cells and anti-PD1 strategies is under investigation. Abstract: The aim of adoptive T-cell therapy is to promote tumor-infiltrating immune cells following the transfer of either tumor-harvested or genetically engineered T lymphocytes. A new chapter in adoptive T-cell therapy began with the success of chimeric antigen receptor (CAR) T-cell therapy. T cells harvested from peripheral blood are transduced with genetically engineered CARs that render the ability to recognize cancer cell-surface antigen and lyse cancer cells. The successes in CAR T-cell therapy for B-cell leukemia and lymphoma have led to efforts to expand this therapy to solid tumors. Herein, we discuss the rationale behind the preclinical development and clinical trials of T-cell therapies in patients with malignant pleural mesothelioma. Furthermore, we highlight the ongoing investigation of combination immunotherapy strategies to synergistically potentiate endogenous as well as adoptively transferred immunity.